Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 2—February 2010


Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1

Anthony T. NewallComments to Author , James G. Wood, Noemie Oudin, and C. Raina MacIntyre
Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (A.T. Newall, J.G. Wood, C.R. MacIntyre); National Institute for Applied Sciences, Lyon, France (N. Oudin)

Main Article

Table 2

Base-case economic results per person in the population (healthcare system perspective) of 4 pharmaceutical-based pandemic influenza mitigation strategies*

Strategy no. Net cost Incremental cost LYS Incremental LYS Incremental cost per LYS†
1 65.88
2 82.24 16.36 0.01803 0.01803 908
3 100.65 18.40 0.03501 0.01698 1,084
4 124.00 23.36 0.03814 0.00313 7,458

*LYS, life-year saved. Costs and life-years discounted at 5% annually; all costs calculated in 2005 Australian dollars.
†Rounded to the nearest whole dollar.

Main Article

1This material was compiled before the declaration of pandemic (H1N1) 2009 and concerns stockpiling for a future influenza pandemic.

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO